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The immunological basis of scarring trachoma is not well understood. It is unclear whether it is driven
primarily through cell-mediated adaptive or epithelial-cell-derived innate responses. The purpose of this study
was to investigate the expression of the inflammatory and fibrogenic mediators which may be involved. We
conducted a cross-sectional survey of children living in an untreated trachoma-endemic community in Tan-
zania. The children were examined for signs of trachoma, and swabs were collected for bacteriological culture
and RNA and DNA isolation. Chlamydia trachomatis was detected by the Amplicor PCR test. The expression of
the following genes was measured by quantitative reverse transcription-PCR (RT-PCR): S100A7, IL1B, IL17A,
IL23A, CXCL5, CCL18, TLR2, NLRP3, KLRD1, CTGF, and MMP9. Four hundred seventy children under the
age of 10 years were included. Follicular trachoma (TF) was detected in 65 children (14%), C. trachomatis was
detected in 25 (5%), and bacterial pathogens were cultured in 161 (34%). TF was associated with significantly
increased expression of S100A7, IL17A, CCL18, CXCL5, and CTGF. Expression was increased further in the
presence of papillary inflammation. Nonchlamydial bacterial infection was associated with increased expres-
sion of IL17A, CXCL5, CCL18, and KLRD1. IL17A expression was associated with increased expression of
S100A7, CXCL5, CCL18, KLRD1, and CTGF. These data are consistent with a role for IL-17A in orchestrating
the proinflammatory response in trachoma. Its activity may be promoted either as part of the cell-mediated
response or through innate pathways. It may drive a range of proinflammatory factors leading to excessive
tissue damage and repair involving fibrosis.
The basis of the immunopathology that characterizes clin-
ically active trachoma and its link to the development of
scarring disease of the conjunctiva remains to be elucidated.
Recurrent chronic episodes of inflammation have been
linked in long-term epidemiological studies to the subse-
quent development of scarring complications (16, 57, 59).
The principal driver for this inflammatory scarring process
in communities where trachoma is endemic is thought to be
infection with Chlamydia trachomatis, although direct evi-
dence is limited (59). The signs of inflammation and the
detection of chlamydial infection may show only a relatively
weak correlation, particularly in low-prevalence settings (8,
9, 60). This relationship weakens after the introduction of
antibiotic treatment (28). Nonchlamydial bacterial patho-
gens have been associated with signs of active trachoma in a
low-prevalence setting and in adults with established scar-
ring (9, 10, 25). These observations raise the possibility that
the chronic inflammatory reaction characterizing trachoma,
which is the hypothesized basis for the development of scar-
ring, may not always require an ongoing replicating chla-
mydial infection. It is possible that transient exposure to
chlamydial antigens in an environment where the disease is
endemic or to other bacteria may be sufficient stimuli to
provoke ongoing active trachoma in individuals previously
infected by C. trachomatis. (50).
Immunopathological correlates of active trachoma have
been investigated using a number of different approaches,
including peripheral blood mononuclear cell (PBMC) re-
sponses to chlamydial antigens (4), tear immunoglobulin
and cytokine detection (5, 19, 48), conjunctival gene expres-
sion analysis by reverse transcription-PCR (RT-PCR) (6, 7),
and, more recently, whole-conjunctival-transcriptome anal-
ysis (35). From this body of work, some broad conclusions
emerge. First, the presence of detectable ocular C. tracho-
matis infection is associated with an activated Th1 response,
characterized by increased expression of gamma interferon
(IFN-) (7, 35). Animal models of genital chlamydial infec-
tion indicate that a Th1 response is probably necessary for
the successful resolution of chlamydial infection, through
IFN--mediated mechanisms (43). Second, clinically active
trachoma in children (irrespective of whether C. trachomatis
is detected) and inflammation in scarred conjunctiva in
adults are associated with a proinflammatory cytokine re-
sponse (7, 11, 35). Third, recent information from whole-
conjunctival-transcriptome analysis in children with active
disease and adults with scarring trachoma found prominent
innate immune responses (11, 35). Finally, there are some
early pointers to the pathways involved in the development
of cicatricial trachoma, with evidence of increased activity of
* Corresponding author. Mailing address: Department of Infectious
and Tropical Diseases, London School of Hygiene and Tropical Med-
icine, Keppel Street, London WC1E 7HT, United Kingdom. Phone: 44
(0) 7958 8359. Fax: 44 (0) 7958 8317. E-mail: matthew.burton@lshtm
.ac.uk.
 Published ahead of print on 12 September 2011.
4977
various matrix metalloproteinases (MMP), which are in-
volved in the regulation of the extracellular matrix (11).
However, the field is far from clear; in particular, the pro-
cesses involved in persistent active disease in childhood
(even in the absence of infection) and how they link to the
development of scarring are not understood. These out-
standing questions are central to the pathophysiology of this
disease, and without an adequate understanding of the pro-
cesses involved, efforts to control the disease, particularly by
vaccination, are likely to be held back.
We have conducted a cross-sectional population-based study
of Tanzanian children living in an untreated trachoma-en-
demic community. We have previously reported the clinical
and microbiological characteristics of this group, which had a
community prevalence of follicular trachoma (TF) of 14% (9).
Although C. trachomatis was detected in 5% of individuals, this
was not associated with the presence of TF. In contrast, non-
chlamydial bacterial pathogens were frequently associated with
TF (9). This raises the possibility that in low-prevalence areas,
at least, nonchlamydial bacterial pathogens may contribute to
the inflammatory process.
Here we report the findings of a conjunctival gene expres-
sion study in the same children from this community, in
whom we measured several factors that might be involved in
the inflammatory response in active trachoma and its link to
the development of scarring. The choice of targets focused
on inflammatory-response mediators, pathogen pattern rec-
ognition receptors, and extracellular-matrix regulators,
guided by results of previous whole-transcriptome studies
(11, 35). The expression of interleukin-17A (IL17A) was
elevated in the presence of follicular and papillary inflam-
mation and was associated with coexpression of proinflam-
matory and profibrotic factors. It is possible that IL-17A and
its related effects lie at the center of the pathogenesis of
trachoma.
MATERIALS AND METHODS
Ethical approval. This study adhered to the tenets of the Declaration of
Helsinki. The Tanzanian National Institute of Medical Research Ethics Com-
mittee, the Kilimanjaro Christian Medical Centre Ethics Committee, and the
London School of Hygiene and Tropical Medicine Ethics Committee approved
the study. Informed consent was documented in writing by the parent/guardian
on behalf of each child before recruitment after the consent form was explained
to the parent/guardian.
Study participants. The study was conducted in a single village in Siha District,
Kilimanjaro region, northern Tanzania. After a census, all children under the age
of 10 years who were present and for whom consent was given were enrolled into
the study. This district had never received mass drug administration for trachoma
control.
Clinical assessment and sample collection. The study procedures have been
previously described (9). Briefly, participants were examined by an ophthalmol-
ogist and clinical signs graded using the 1981 WHO Trachoma Grading System
(follicles, papillae, and conjunctival scarring [FPC]) (15). Follicular trachoma
(TF) is equivalent to an FPC follicular score of 2 or 3 (F2/F3) (51). Three swab
samples were collected from the anesthetized conjunctiva. A rayon-tipped swab
sample was collected for microbiological culture from the inferior fornix, placed
immediately into Amies-charcoal transport media (Sterilin, Caerphilly, United
Kingdom), and kept at ambient temperature until processed in the laboratory
later the same day. A second, Dacron polyester-tipped swab (Hardwood Prod-
ucts Company) was collected from the left upper tarsal conjunctiva for RNA
extraction and placed directly into a tube containing 0.3 ml of RNAlater (Life
Technologies, Paisley, United Kingdom). A third swab was collected for detec-
tion of C. trachomatis. These two samples were collected in a standardized
manner from parallel strips of tarsal conjunctiva and passed firmly four times
across the conjunctiva with a quarter turn between each pass. They were kept on
ice packs until frozen later the same day at 80°C. The examiner changed gloves
before examination and collection of swabs from each child. “Negative field
controls” were collected after every 50 subjects by passing the swab through the
air a few centimeters in front of a seated study participant. The population of
the village was mass treated with single-dose oral azithromycin immediately
after the survey, as per WHO guidelines.
Tests for conjunctival infection. Microbiology samples were inoculated onto
blood and chocolate agar plates (usually less than 6 h from collection time) and
incubated at 37°C for 48 h. Culture isolates were identified by standard micro-
biological techniques. Staphylococcus epidermidis, Corynebacterium spp., Viridans
group Streptococcus, and Bacillus spp. were designated commensal organisms
and excluded from the analysis of bacterial pathogens. To detect C. trachomatis,
DNA was extracted from the dry swab using the QIAamp DNA minikit
(Qiagen, Crawley, United Kingdom) and tested using the Amplicor CT/NG
kit (Roche Molecular Systems, Branchburg, NJ), with previously described
modifications (8, 24).
Quantitative RT-PCR for conjunctival gene expression. The abundance of 11
selected transcripts was estimated by quantitative RT-PCR. We selected a range
of factors that are possibly involved in the inflammatory and fibrogenic processes
that lead to scarring trachoma. The choice of targets was informed by two
previously published conjunctival-transcriptome analyses conducted on samples
from children with active trachoma in The Gambia, from matched healthy
controls, and from Ethiopian adults with trachomatous trichiasis (11, 35). These
targets fall broadly into several groups: proinflammatory cytokines, chemokines,
or effector molecules (interleukin-1 [IL1B], interleukin-17A [IL17A], interleu-
kin-23A [IL23A], psoriasin-1 [S100A7], chemokine [CXC] ligand-5 [CXCL5],
and chemokine [C-C motif] ligand 18 [CCL18]), extracellular-matrix modifiers
(matrix metalloproteinase 9 [MMP9] and connective tissue growth factor
[CTGF]), pattern recognition receptors (NLR family pyrin domain-containing 3
[NLRP3] and Toll-like receptor 2 [TLR2]), and a natural killer (NK) cell marker
(killer cell lectin-like receptor subfamily D, member 1 [KLRD1]).
Total RNA was extracted from the swab samples using the RNeasy microkit
(Qiagen). Reverse transcription was performed using the QuantiTect reverse
transcription kit (Qiagen) according to the manufacturer’s instructions. This
contains a mix of oligo(dT) and random primers. Multiplex real-time quantita-
tive PCR was performed on a Rotor-Gene 6000 (Corbett Research, Cambridge,
United Kingdom) using the QuantiTect Multiplex NoROX kit (Qiagen, Crawley,
United Kingdom), according to the manufacturer’s instructions. Multiplex assays
of up to four separate targets (including HPRT-1 as the reference gene) were
designed by Sigma Life Science using Beacon Designer 7.60 (Premier Biosoft
International, Palo Alto, CA). The primer and probe concentration in each
reaction mixture was 0.2 M. The thermal cycle protocol used the following
conditions: 95°C for 15 min, followed by 45 cycles of (i) denaturation at 94°C for
30 s and (ii) annealing and extension at 60°C for 30 s. Fluorescence data were
acquired at the end of each cycle. The relative efficiencies of the component
reactions were assessed using standards containing all targets in a sequence of
10-fold serial dilutions. Reactions were performed in duplicate, in a total volume
of 25 l, which contained 2 l of sample or standard. Probe and primer se-
quences are available upon request.
Analysis. Data were managed in Access (Microsoft) and analyzed in STATA
11 (StataCorp). The transcript abundances for genes of interest were standard-
ized relative to that of HPRT-1 in the same reaction using the CT method
(where CT is threshold cycle) and were normalized by log10 transformation (29).
For several genes (IL23A, CCL18, TLR2, NLRP3, KLRD1), the target abun-
dance was measured in singleplex assays, because it was not possible to multiplex
with these other targets. Therefore, the quantitation for these targets relative to
HPRT is based upon standard curve analysis. The relative levels of expression of
genes of interest were compared using unpaired t tests for the presence of
follicular inflammation (F2/F3), papillary inflammation (P2/P3), and bacterial
pathogens on culture. Multivariable linear-regression models were fitted for the
expression level of each target for the following potential explanatory variables:
sex (female), age (in years), follicular inflammation (F2/F3), and the detection of
a bacterial pathogen by culture. A stepwise selection process was performed to
fit each model using likelihood ratio testing, with terms retained if the P value for
omission was 0.2. Correlation coefficients and partial correlation coefficients
(which take account of the lack of independence of gene expression) between
IL17A and the other targets were calculated. To adjust for multiple comparisons,
we calculated critical significance thresholds for each table using the conservative
Bonferroni correction. Although we make several comparisons, these are un-
likely to be truly independent of each other, as one would expect some of these
genes to interact in biological networks.
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RESULTS
Study participants and samples. The study participants have
been described previously (9). Briefly, we examined 571/700
(81.5%) children 10 years of age living in the village. At
recruitment, 75 (58%) were absent, 29 (23%) refused partici-
pation, and 25 (19%) were too young. Results of gene expres-
sion, bacteriology, and C. trachomatis PCR were available for
a total of 470/571 (82.3%) children. When we compared the
470 children for whom results were obtained and all the other
230 children said to be living in the village, there was no
difference in either the mean ages (4.85 versus 4.79 years; P 
0.80) or the proportions who were of male gender (49.2%
versus 44.4%; P  0.23). These 470 children were slightly
younger than the 101 children who were examined but did not
have all three sets of results (4.85 years versus 5.50; P  0.05),
but similar proportions were male (49.2% versus 41.6%; P 
0.17). All subsequent analyses were limited to the 470 children
with all laboratory results available.
Clinical signs and infection. The relationship between the
clinical signs and both C. trachomatis infections and other
bacterial infections in this sample has been previously reported
in detail (9). Briefly, TF was diagnosed in 65 (13.7%) children.
The frequencies of the FPC grading system follicular (F) and
papillary (P) inflammation scores are shown in Table 1. C.
trachomatis DNA was detected by Amplicor CT/NG PCR in 25
(5.3%) samples, and bacterial pathogens were cultured from
161 (34.3%) eyes. Streptococcus pneumoniae and Haemophilus
influenzae accounted for 89.7% of the pathogenic bacterial
isolates (9). All negative field controls tested negative by Am-
plicor C. trachomatis PCR. The frequencies of C. trachomatis
PCR-positive and cultured bacterial pathogens by clinical
grade are shown in Table 1. There was no association between
the presence of TF and the detection of C. trachomatis (odds
ratio [OR], 1.20; 95% confidence interval [95%CI], 0.40 to
3.61; P  0.75). There was, however, a significant association
between the presence of TF and the culture of a bacterial
pathogen (OR, 4.69; 95%CI, 2.31 to 9.52; P  0.001).
Gene expression in active trachoma and infection. The lev-
els of expression of the genes relative to the presence of clinical
features of trachomatous conjunctival inflammation are shown
in Table 2. Significantly increased expression of S100A7,
IL17A, CXCL5, CCL18, and CTGF was found in the presence
of both follicular inflammation (F2/F3) and papillary inflam-
mation (P2/P3); the critical significance threshold was a P of
0.0015 (Bonferroni correction for 33 comparisons). The fold
changes were greater in the presence of papillary inflammation
than in the presence of follicular inflammation for each of
these five targets. There were no differences in gene expression
in the presence of C. trachomatis detected by Amplicor CT/NG
(data not shown), possibly due to the small numbers of infec-
tions. In contrast, the presence of a nonchlamydial bacterial
pathogen was associated with significantly increased expression
of IL17A, CXCL5, CCL18, TLR2, NLRP3, KLRD1, and
CTGF; there were also borderline increases in the expression
of S100A7 and IL23A. Multivariable linear-regression models
for the expression of each target indicated that, after adjust-
ment for gender, age, and the presence of bacterial pathogens,
follicular trachoma (F2/F3) was significantly associated with
increased expression of S100A7, IL17A, CXCL5, CCL18, and
CTGF (Table 3). The correlation between the expression levels
of IL17A and the other targets is shown in Table 4.
TABLE 1. Clinical signs, C. trachomatis infection,
and bacterial infectiona
Type of inflammation
and clinical sign
Clinical
grade
C. trachomatis
infection
Bacterial
infection
No. of
children %
No. of
children %
b No. of
children %
b
Follicular
Presence of follicular
trachomatous
inflammation
No 405 86.2 21 5.2 121 29.9
Yes 65 13.8 4 6.2 40 61.5
FPC score of:
F0 321 68.3 13 4.0 94 29.3
F1 84 17.9 8 9.5 27 32.1
F2 35 7.4 2 5.7 22 62.9
F3 30 6.4 2 6.7 18 60.0
Papillary
Presence of intense
trachomatous
inflammation
No 464 98.7 25 5.4 158 34.1
Yes 6 1.3 0 0.0 3 50.0
FPC score of:
P0 369 78.5 16 4.3 112 30.4
P1 69 14.7 5 7.3 32 46.4
P2 26 5.5 4 15.4 14 53.9
P3 6 1.3 0 0.0 3 50.0
a Prevalences of clinical signs of active trachoma in 470 children in the study.
The prevalences of C. trachomatis infection (as determined by Amplicor PCR)
and other bacterial pathogens (as determined by culture, excluding commensal
organisms) are given for TF and trachomatous inflammation scores of the sim-
plified WHO system and the individual follicular (F) and papillary (P) inflam-
mation grades of the FPC system.
b This percentage is for the number infected within each clinical disease grade.
TABLE 2. Gene expression level by follicular inflammation,
papillary inflammation, and bacterial infectiona
Target
Follicular
inflammation
(F2/F3)
Papillary
inflammation
(P2/P3)
Bacterial
infection
FC P value FC P value FC P value
S100A7 2.49 0.0001 2.61 0.0002 1.51 0.003
IL1B 1.20 0.33 1.24 0.39 1.28 0.07
IL17A 3.32 0.0001 5.53 0.0001 2.43 0.0001
IL23A 1.23 0.06 1.17 0.30 1.25 0.005
CXCL5 4.16 0.0001 9.52 0.0001 2.19 0.0001
CCL18 3.38 0.0001 7.82 0.0001 2.66 0.0001
NLRP3 1.18 0.05 1.21 0.09 1.23 0.0005
KLRD1 1.29 0.01 1.11 0.45 1.61 0.0001
TLR2 1.20 0.004 1.19 0.04 1.16 0.0012
CTGF 2.22 0.0001 2.52 0.0001 1.42 0.0001
MMP9 1.22 0.04 1.23 0.12 1.05 0.48
a Gene expression levels were determined for children with follicular inflam-
mation, papillary inflammation, and bacterial infection (by culture, with com-
mensal organisms excluded). The fold changes (FC) in gene expression are
derived from comparisons of children with follicular inflammation (F2 or F3)
versus no follicular trachoma (F0 or F1), papillary inflammation (P2 or P3)
versus no papillary inflammation (P0 or P1), and bacterial infection versus no
bacterial infection. P values are for the unpaired t test. Using the Bonferroni
correction for multiple comparisons, the critical significance threshold level is a
P value of 0.0015.
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DISCUSSION
At the epidemiological level, trachomatous conjunctival in-
flammation in childhood is linked to subsequent scarring (16,
57, 59). The molecular basis for this process, which has re-
ceived relatively little attention in trachoma research due to
the difficulty of conducting such studies, is not understood. In
this cross-sectional population-based study, we found that fol-
licular and papillary inflammations were associated with in-
creased expression of IL17A, S100A7, CXCL5, CCL18, and
CTGF and that nonchlamydial bacterial infection was associ-
ated with increased expression of IL17A, CXCL5, CCL18, and
KLDR1.
Animal and human studies suggest that successful resolution
of C. trachomatis infection probably involves an IFN--depen-
dent Th1 cell-mediated immune (CMI) response (43, 44).
However, the immunopathogenic basis of the scarring compli-
cations of ocular and genital tract infections is not well under-
stood (14). Several theories for pathogenesis (none of which
entirely fit the available data), which fall into two broad par-
adigms, immunological (cell mediated) and cellular (innate)
(49), have been proposed.
The immunological paradigm suggests that immunopathol-
ogy results from various antigen-specific CMI responses (14,
50). In a classical delayed-type hypersensitivity reaction, Th1
responses are enhanced on rechallenge. Models of repeated C.
trachomatis infection that develop scarring are characterized
by T lymphocytes and Th1 cytokine production, possibly link-
ing these to tissue-damaging inflammation (53). However, peo-
ple with established trachomatous scarring and current infec-
tion have weaker PBMC Th1 responses when stimulated with
C. trachomatis antigens, leading some to reject this mechanism
(23, 49). Th2-dominated responses, mediated through IL-13
and alternatively activated macrophages (AAM), are linked
to several scarring diseases, for example, ocular cicatricial
pemphigoid and hepatic fibrosis in schistosomiasis (47, 61).
However, there is currently little evidence for this mechanism
in trachoma. PBMCs from cases with severe scarring more
frequently produced IL-4 and less frequently produced IFN-
than PBMCs from controls when they were stimulated with C.
trachomatis antigens (23). However, conjunctival-transcrip-
tome profiling of adults with established scarring found lower
TABLE 3. Multivariable linear-regression models for the
expression of each targeta
Target and parameter FC P value
S100A7
Gender (female) 0.68 0.003
Age (yr) 1.04 0.11
Follicular trachoma (F2/F3) 2.39 0.0001
Bacterial infection 1.37 0.03
IL1B
Gender (female)
Age (yr) 0.96 0.13
Follicular trachoma (F2/F3)
Bacterial infection 1.22 0.16
IL17A
Gender (female) 1.15 0.18
Age (yr) 0.92 0.0001
Follicular Trachoma (F2/F3) 2.53 0.0001
Bacterial infection 1.83 0.0001
IL23A
Gender (female) 0.86 0.04
Age (yr)
Follicular trachoma (F2/F3) 1.17 0.17
Bacterial infection 1.22 0.02
CXCL5
Gender (female)
Age (yr) 0.94 0.06
Follicular trachoma (F2/F3) 3.40 0.0001
Bacterial infection 1.64 0.008
CCL18
Gender (female)
Age (yr) 0.93 0.0004
Follicular trachoma (F2/F3) 2.55 0.0001
Bacterial infection 2.05 0.0001
NLRP3
Gender (female)
Age (yr) 0.98 0.02
Follicular trachoma (F2/F3)
Bacterial infection 1.19 0.004
KLRD1
Gender (female)
Age (yr) 0.91 0.0001
Follicular trachoma (F2/F3)
Bacterial infection 1.42 0.0001
TLR2
Gender (female) 0.95 0.19
Age (yr) 0.99 0.15
Follicular trachoma (F2/F3) 1.16 0.02
Bacterial infection 1.11 0.02
CTGF
Gender (female)
Age (yr) 0.97 0.03
Follicular trachoma (F2/F3) 2.04 0.0001
Bacterial infection 1.20 0.04
MMP9
Gender (female)
Age (yr)
Follicular trachoma (F2/F3) 0.82 0.04
Bacterial infection
a Terms were retained in the model if their P value was 0.2, by likelihood
ratio testing. FC, fold changes, which were derived from the models. The specific
comparisons within these terms of the model were female versus male, age as a
continuous variable in years, follicular trachoma (F2 or F3) versus no follicular
trachoma (F0 or F1), and bacterial infection versus no bacterial infection. Using
the Bonferroni correction for multiple comparisons, the critical significance
threshold level is a P value of 0.0016.
TABLE 4. Correlation and partial correlation coefficients for the
expression of IL17A compared to that of
the other measured targetsa
Target Correlationcoefficient
Partial correlation
coefficient P value
S100A7 0.3392 0.1880 0.0001
IL1B 0.1921 0.0637 0.18
IL23A 0.2095 0.0043 0.93
CXCL5 0.5185 0.3191 0.0001
CCL18 0.5201 0.2215 0.0001
NLRP3 0.1925 0.0144 0.76
KLRD1 0.2454 0.1870 0.0001
TLR2 0.3233 0.0157 0.74
CTGF 0.4910 0.2933 0.0001
MMP9 0.1590 0.1292 0.006
a The P value refers to the partial correlation coefficient. Using the Bonferroni
correction for multiple comparisons, the critical significance threshold level is a
P value of 0.005.
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IL13 expression, a marked increase in nitric oxide synthase 2A
(NOS2A) expression, and only a slight increase in arginase-1
(ARG1) expression, consistent with predominantly classically
activated macrophage activity (11, 24, 62). Similarly, IL-13 has
been detected less frequently in tear fluid from individuals with
trachomatous scarring than from controls (48). Previous stud-
ies of active trachoma in children have examined factors linked
to a Th2 response, with inconclusive results. IL4 expression has
been detected more frequently in children with active tra-
choma and chlamydial infection than in control children, al-
though a separate study found no difference in the tear IL-4
concentrations (7, 48). Conjunctival-transcriptome analysis of
children with active chlamydial infection found widespread
evidence of IFN- activity but relatively little to suggest Th2
activity (35).
In the cellular paradigm, inflammatory responses are initi-
ated and sustained by the innate immune system through pat-
tern recognition receptors (PRRs), particularly on epithelial
cells (14, 49). In vitro infection of epithelial cell cultures with C.
trachomatis results in the production of several proinflamma-
tory cytokines (45). Microarray transcriptome data indicate
prominent innate immune responses in trachoma, consistent
with this cellular paradigm (11, 35). However, neither of these
two paradigms provides a satisfactory explanation for the
pathogenesis of trachoma on its own; they are not mutually
exclusive and have common characteristics.
Expression of IL17A was enriched in the presence of signs of
active trachoma and correlated with the expression of CXCL5,
S100A7, CCL18, and CTGF. IL-17A, a member of the inter-
leukin-17 superfamily, is a cytokine which contributes not only
to defense, especially against extracellular bacteria, but also to
immune-mediated pathology in various diseases (37). It was
originally described to arise from a distinct class of T-helper
cells (Th17), which develop under the combined stimulation of
transforming growth factor  (TGF-), IL-1, IL-6, and IL-23
(37). Other cell types also produce IL-17A: 	 T cells, NK
cells, macrophages, and possibly neutrophils and epithelial
cells (46). IL-17A has profound proinflammatory effects that
can lead to extensive tissue damage, particularly mediated
through neutrophils (37). These include the induction of
chemokines, S100 proteins, and matrix metalloproteinases
(37). The stimulation of Th17 cells to produce IL-17A is anti-
gen specific. However, IL-17A production may also occur
through innate pathways, with signaling through receptors such
as TLR2 leading to IL-17A production by Th17 cells, 	 T
cells, and NK cells (46). The regulation of IL-17A and Th17
cells is complex; they appear negatively regulated by Th1 (IFN-
), Th2 (IL-4), and Treg (IL-10, TGF-) cells. The balance
between Th1 and Th17 appears critical, with excessive Th17
activity leading to immunopathology. Recent observations
about IL-17A and Th17 cells in another intracellular bacterial
infection, Mycobacterium tuberculosis, may be instructive and
may conceivably have parallels in chlamydial infection (52). In
a murine model of M. tuberculosis lung infection, subsequent
repeated vaccination with BCG led to extensive tissue damage
by neutrophils, and this damage was IL-17 dependent and was
without the loss of Th1-mediated immunity to M. tuberculosis.
Repeated exposure to BCG antigen led to amplification in the
Th17 response, which became refractory to regulation by IFN-
/Th1. It is possible that in trachoma a similar imbalance
between Th1 and Th17 responses may arise from repeated C.
trachomatis infection or exposure to chlamydial antigens.
While the resolution of infection may be unaffected, the tissue
may experience augmented inflammatory responses not only to
chlamydia but also to nonspecific triggers, such as other bac-
teria, through innate response mechanisms. It is interesting to
note that IL17A expression was increased in children with
bacterial infection. These observations suggest a possible role
for IL-17A in the development of the inflammatory pathology
in trachoma.
Psoriasin (S100A7), a member of the S100 family, was ini-
tially identified in psoriatic skin lesions and is closely associ-
ated with inflammatory epithelial pathology (17, 30). S100A7
production is triggered by some bacterial components through
PRRs and by proinflammatory cytokines (2, 22, 56). It is con-
stitutively expressed in ocular surface epithelium and increases
in corneal epithelial cell culture upon stimulation with bacte-
rial antigens and proinflammatory cytokines (IL-1, tumor ne-
crosis factor alpha [TNF-
]) (18). Psoriasin is an important
antimicrobial peptide protecting epithelial surfaces from bac-
terial infection (20, 32). The antimicrobial action is possibly
mediated through pore formation or zinc sequestration (20,
33). S100A7 is chemotactic for both neutrophils and T lym-
phocytes and may be important in driving the local innate
immune response (27, 58). It stimulates neutrophils to produce
proinflammatory cytokines and reactive oxygen species and
induces degranulation (64). Others have suggested that
S100A7 stimulates keratinocytes to produce cytokines that
promote a Th1/Th17 response (58). Stimulation of keratino-
cytes with a combination of IL-17, IL-22, and TNF-
 (pro-
duced in a Th1/Th17 response) increased S100A7 production,
which may form a feedback loop, amplifying inflammation
(58). Previously, we found increased S100A7 expression in
adults with scarring trachoma, both with and without concur-
rent conjunctival inflammation (11) and by microarray analysis
of active trachoma in children (35). Interestingly, S100A7 is
also expressed at increased levels in the conjunctivas of indi-
viduals with recurrent trichiasis following surgery, after con-
trolling for preoperative disease severity (unpublished data).
Increased S100A7 expression in active trachoma, indepen-
dently of bacterial infection, suggests a potential role for pro-
voking and sustaining the inflammatory clinical phenotype,
which warrants investigation.
Expression of CXCL5 was significantly increased in active
trachoma, independently of bacterial infection. Similar in-
creased expression has previously been found in scarring tra-
choma (11) and by microarray analysis of active trachoma in
children (35). CXCL5 induces neutrophil chemotaxis and ac-
tivation; it also induces fibroblast precursor chemotaxis and
differentiation (36). Therefore, it could conceivably contribute
to inflammation and fibrosis. Epithelial cells are probably the
main source of CXCL5, although macrophages and fibroblasts
may also contribute. Epithelial cell lines have been shown to
produce CXCL5 in response to chlamydial infection, which led
to neutrophil chemotaxis (63). Animal models of pulmonary
inflammation have demonstrated CXCL5 production in re-
sponse to bacterial antigens through TLR4-dependent signal-
ing (26). It is therefore possible that in the context of cicatricial
trachoma, other bacterial pathogens stimulate CXCL5 produc-
tion directly or indirectly through other cytokines (IL-1,
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TNF-
) or products of extracellular-matrix breakdown (e.g.,
actin) (54).
The Th2 chemokine CCL18 had the largest increase in ex-
pression of the CC chemokines detected by microarray analysis
of active disease with concurrent chlamydial infection (35). We
found that CCL18 expression significantly increased in associ-
ation with both follicular trachoma and bacterial infection.
CCL18 is produced by AAM in response to Th2 cytokines. It
is closely associated with tissue fibrosis in sarcoidosis, systemic
sclerosis, and idiopathic pulmonary fibrosis and is a reliable
biomarker for progressive pulmonary fibrosis (31, 40–42).
CCL18 promotes lymphocyte chemotaxis and the development
of a T-regulatory phenotype, with production of TGF- and
IL-10, but not IFN- or IL-4 (12). Finally, CCL18 markedly
increases collagen type 1 production by fibroblasts in vitro (39).
The finding of a consistent association in two separate popu-
lations between active trachoma and increased CCL18 expres-
sion suggests a potential role for this chemokine in linking
inflammatory trachoma in childhood to the development of
scarring. In view of the reported link between Th2 responses
and CCL18, it is possible that this chemokine may reflect some
subtle underlying Th2 activity in active trachoma that is ob-
scured by the more florid IFN- response.
There are several well-characterized mediators and path-
ways in human scarring diseases (61). The archetypal profi-
brotic molecule is TGF-. However, there are other potent
profibrotic factors, such as CTGF, platelet-derived growth fac-
tor (PDGF), and IL-13. The observation that CTGF expression
is significantly increased in active trachoma may indicate an-
other mechanistic link between the childhood disease and the
development of scarring. CTGF has previously been found in
conjunctival stromal macrophages in tissue from children with
active trachoma (3). CTGF is an important profibrotic medi-
ator in several fibrotic disease processes, including renal and
hepatic fibrosis and systemic sclerosis (1, 13, 21). Its expression
is regulated by TGF- (38). It has direct profibrotic effects and
also mediates the effect of TGF-; the two act synergistically
(38, 55). There is a suggestion that for persistent tissue fibrosis
to develop, CTGF is required in addition to TGF-; in the
absence of CTGF, TGF--induced fibrosis may have a revers-
ible quality (34). CTGF stimulates fibroblasts to migrate, pro-
liferate, and produce extracellular matrix. It also stimulates the
transition from epithelial cells to mesenchymal cells, the im-
portance of which is unknown in scarring trachoma. The study
of TGF- in trachoma has proved challenging because of its
complex posttranscriptional regulation. A previous gene ex-
pression study found TGF2 to be constitutively expressed in
the conjunctiva across disease groups (7). CTGF expression
may therefore offer an indirect way of investigating TGF-
activity.
The association between bacterial pathogens and the in-
creased expression of several factors in this study is noteworthy
and has previously received limited attention. The data in this
study suggest that these other infections appear to have an
effect on the expression of factors which may contribute to the
scarring process. It is possible that repeated conjunctival ex-
posure to C. trachomatis leads to altered, excessively inflam-
matory responses to other pathogens, resulting in a clinical
phenotype that not only is indistinguishable from follicular
conjunctivitis caused by C. trachomatis but also is associated
with a similar profibrotic inflammatory response. We think that
this is an area that warrants further investigation.
Caution needs to be exercised in the interpretation of cross-
sectional studies when results are extrapolated to longitudinal
disease processes. Second, we can report only associations, but
these are useful for the development of new hypotheses and
further investigation. Longitudinal studies are needed to inves-
tigate potential causal links between specific immunological
responses and progressive scarring disease. Gene expression
analysis of conjunctival surface swab samples has the advan-
tage that it is an acceptable, noninvasive investigation; how-
ever, it may yield a biased cell population, and the presence of
a functional protein can only be inferred. In this study popu-
lation, the burden of chlamydial infection was low. This limits
what this data set can tell us about the responses to the infec-
tion itself; however, it is helpful in the exploration of the
potential basis of the active trachoma phenotype after the
infection has resolved.
In summary, we found evidence of enriched expression of
IL17A in association with the signs of active trachoma. This
was associated with increased expression of S100A7, CXCL5,
CCL18, and CTGF. This raises the possibility of IL-17A and
Th17 activity being important in the development of the in-
flammatory pathology that leads to scarring trachoma. The
increased chemokine responses are likely to result in increased
neutrophil chemotaxis and activation. This would lead to
greater tissue damage, which, if prolonged, would result in
fibrosis as part of the wound healing response. IL-17A and
Th17 cells provide a link between the adaptive and innate
responses in chlamydial infection, possibly providing a unifying
explanation for the two disease paradigms and explaining how
this organism causes disease.
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